Mass layoffs at the inventor of aspirin show that Bayer, the German maker of drugs and seeds, has more headaches than its Monsanto hangover. The conglomerate’s health care division, which provides more than half its revenue, needs urgent attention. Bayer will begin losing patent protection for two blockbuster drugs in the next five years and has little under development to compensate.